Literature DB >> 24291041

Discovery and optimization of Lu AF58801, a novel, selective and brain penetrant positive allosteric modulator of alpha-7 nicotinic acetylcholine receptors: attenuation of subchronic phencyclidine (PCP)-induced cognitive deficits in rats following oral administration.

Jørgen Eskildsen1, John P Redrobe2, Anette G Sams2, Kim Dekermendjian2, Morten Laursen2, Jette B Boll2, Roger L Papke3, Christoffer Bundgaard2, Kristen Frederiksen2, Jesper F Bastlund2.   

Abstract

In this Letter, we describe a chemical lead optimization campaign starting from a novel, weak α7 nicotinic acetylcholine receptor positive allosteric modulator (PAM) hit from a HTS screen. Exploration of the structure-activity relationships for α7 PAM potency, intrinsic hepatic clearance, the structure-property relationships for lipophilicity, and thermodynamic solubility, led to the identification of Lu AF58801: a potent, orally available, brain penetrant PAM of the α7 nicotinic acetylcholine receptor, showing efficacy in a novel object recognition task in rats treated subchronically with phencyclidine (PCP).
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Electrophysiology; Lead optimization; Nicotinic acetylcholine receptors; Novel object recognition; Positive allosteric modulator

Mesh:

Substances:

Year:  2013        PMID: 24291041     DOI: 10.1016/j.bmcl.2013.11.022

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

1.  Pro-cognitive activity in rats of 3-furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic acetylcholine receptor.

Authors:  A Potasiewicz; T Kos; F Ravazzini; G Puia; H R Arias; P Popik; A Nikiforuk
Journal:  Br J Pharmacol       Date:  2015-10-10       Impact factor: 8.739

2.  Discovery of BNC375, a Potent, Selective, and Orally Available Type I Positive Allosteric Modulator of α7 nAChRs.

Authors:  Andrew J Harvey; Thomas D Avery; Laurent Schaeffer; Christophe Joseph; Belinda C Huff; Rajinder Singh; Christophe Morice; Bruno Giethlen; Anton A Grishin; Carolyn J Coles; Peter Kolesik; Stéphanie Wagner; Emile Andriambeloson; Bertrand Huyard; Etienne Poiraud; Dharam Paul; Susan M O'Connor
Journal:  ACS Med Chem Lett       Date:  2019-03-25       Impact factor: 4.345

Review 3.  Nicotinic Acetylcholine Receptor Ligands, Cognitive Function, and Preclinical Approaches to Drug Discovery.

Authors:  Alvin V Terry; Patrick M Callahan
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

Review 4.  α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future.

Authors:  Alvin V Terry; Patrick M Callahan
Journal:  Neuropharmacology       Date:  2020-03-15       Impact factor: 5.250

Review 5.  Cholinergic Modulation of Neuroinflammation: Focus on α7 Nicotinic Receptor.

Authors:  Roberta Piovesana; Michael Sebastian Salazar Intriago; Luciana Dini; Ada Maria Tata
Journal:  Int J Mol Sci       Date:  2021-05-06       Impact factor: 5.923

Review 6.  Therapeutic Targeting of α7 Nicotinic Acetylcholine Receptors.

Authors:  Roger L Papke; Nicole A Horenstein
Journal:  Pharmacol Rev       Date:  2021-07       Impact factor: 18.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.